Synchronous tuberculosis, Epstein-Barr virus-associated lymphoproliferative disorder and cytomegalovirus infection in an allogeneic transplant recipient: a case report by unknown
a SpringerOpen Journal
Ostendorf et al. SpringerPlus 2014, 3:278
http://www.springerplus.com/content/3/1/278CASE STUDY Open AccessSynchronous tuberculosis, Epstein-Barr
virus-associated lymphoproliferative disorder and
cytomegalovirus infection in an allogeneic
transplant recipient: a case report
Benjamin Nils Ostendorf1*, Christian Friedrich Jehn1, Lam Giang Vuong1, Hendrik Nogai1, Philipp Guido Hemmati1,
Bernhard Gebauer2, Olaf Penack1, Igor Wolfgang Blau1, Ioannis Anagnostopoulos3 and Renate Arnold1Abstract
Background: Allogeneic stem cell transplant recipients are prone to infections by various organisms. Tuberculosis
(TB) represents a rare infectious complication, especially in countries non-endemic for TB.
Case report: Here, we report the case of a German patient with exposure to TB decades before he was diagnosed
with disseminated TB as well as synchronous Epstein-Barr virus associated lymphoproliferative disorder and
cytomegalovirus infection after allogeneic stem cell transplantation for refractory acute myeloid leukemia.
Tuberculostatic and virostatic therapy was administered and the patient could be discharged with no apparent
signs of infection two weeks after initiation of therapy.
Conclusion: This case illustrates the need for awareness of mycobacterial infections in patients from non-endemic
regions undergoing stem cell transplantation even if other reasons for fever are present.
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Infections are a major reason for morbidity and mortality
in patients undergoing allogeneic hematopoietic stem cell
transplantation (ASCT). Tuberculosis (TB) remains a major
health threat in many parts of the world. However, TB is
rare in non TB-endemic countries, including immunocom-
promised patients after ASCT with reported rates ranging
between less than 1% in the US and up to 16% in Pakistan
(Russo et al. 2010). For Europe, mycobacterial infections in
ASCT recipients have been reported at a rate of 0.79%
(Cordonnier et al. 2004). Usually, TB affecting transplant
patients in countries with low TB prevalence is confined to
foreign-born patients (Garces Ambrossi et al. 2005).
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cleic acids has improved sensitivity. The diagnosis is dif-
ficult because TB infection can present with clinical and
radiological signs resembling infections caused by other,
more frequent pathogens, such as fungi. In addition, TB
is not often considered in the initial differential diagnosis
in febrile patients after ASCT due to its low incidence in
this population. Here, we report the case of a German
man who underwent ASCT and developed pulmonary
and nodular TB in addition to pulmonary cytomegalo-
virus (CMV) infection and Epstein Barr-virus (EBV)-
associated lymphoproliferation.Case description
In July 2012 a 51-year-old German male patient was
diagnosed with acute myeloid leukemia with maturation.
The disease proved refractory after administration of two
cycles of induction chemotherapy and ASCT from a non-
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apy in December 2012. Conditioning consisted of the
FLAMSA-RIC regimen (fludarabine 120 mg/m2, cytarabine
8,000 mg/m2, amsacrine 400 mg/m2, total body irradiation
4 Gy, cyclophosphamide 120 mg/kg and anti-thymocyte
globulin (ATG, Fresenius, 60 mg/kg). Graft-versus-host dis-
ease (GVHD) prophylaxis was cyclosporine A from day −2
(target serum trough level of 180–220 μg/l) and mycophe-
nolate mofetil from day 0 (2 g/day). Ciprofloxacin, acyclovir,
voriconazole and monthly pentamidine inhalations were
administered as anti-infective prophylaxis. Pre-transplant
X-ray of the lungs did not show any pathologic findings
and polymerase chain reactions (PCR) for CMV and EBV
genomes in the peripheral blood were negative. The patient
reported exposure to TB in an affected classmate decades
ago but denied previous infection. BCG vaccination status
was unknown. Tuberculin skin test is not routinely per-
formed at our institution. The patient tolerated the condi-
tioning regime well and received a non T-cell-depleted
peripheral blood stem cell allograft containing 4.9 ×
106 CD34+ cells/kg and 76.8 × 106 CD3+ cells/kg.
From day +5 granulocyte-stimulating factor (5 μg/kg/day)
was given intravenously until the absolute leukocyte count
exceeded 1 × 109/l.
On day +1 after transplantation the patient developed
fever of up to 38.5°C and the antibiotic treatment was
switched to meropenem. After detection of Staphylococ-
cus haemolyticus in a blood culture, vancomycin was
added and the fever subsequently subsided. On day +8
fever recurred and vancomycin was exchanged for linezo-
lid. Computer tomography (CT) of the lungs revealed
micronodular lesions suspicious of calcified granulomas
but did not show signs of acute pulmonary infection. Sub-
sequently, the fever ceased and engraftment of neutrophils
was achieved on day +19.
On day +26 fever was noted again and antibiotic treat-
ment was re-initiated with piperacillin/tazobactam, which
was exchanged for meropenem/vancomycin and then
meropenem/linezolid after persistence of fever. Thoracic
CT-scan showed multiple small pulmonary nodules and
due to the morphology of the lesions pulmonary mycosis
and extramedullary leukemia were primarily considered.
On day +34 right cervical lymphadenopathy was noted
and ultrasonography confirmed three enlarged, inhomo-
geneous and echopenic lymph nodes with a maximum
size of 14×15 mm. Histological analysis of one extirpated
lymph node showed complete effacement of its architec-
ture due to multiple epithelioid cell granulomas with only
occasional necrosis (Figure 1a,b). In addition, focal poly-
morphous lymphoid infiltrates (Figure 1c) composed of
blastic activated B cells expressing CD20 and CD30 were
identified, which were accompanied by plasma cells with
polytypic expression of the immunoglobulin light chains.
Further immunohistological investigations revealed thatthe activated B-blasts expressed the EBV encoded latent
membrane protein-1 and the nuclear antigen EBNA2,
both of which are involved in EBV-induced B cell acti-
vation and proliferation (Figure 1d) (Thorley-Lawson
2001). As a sign of a transition of the latent to the lytic
EBV infection phase several lymphoid cells expressed
the BamHI Z fragment leftward open reading frame 1
(BZLF1)-protein of the virus. Gene rearrangement ana-
lysis of the immunoglobulin heavy chains detected the
presence of a monoclonal B-cell population. These find-
ings led to the diagnosis of an EBV-associated poly-
morphic post-transplantation lymphoproliferative disorder
combined with granulomatous lymphadenitis. Cultures
remained sterile and microscopic examination revealed no
acid-fast bacilli. However, PCR analysis of the lymph node
revealed presence of Mycobacterium tuberculosis (M.
tuberculosis) consensus sequences. Repeated thoracic CT
showed mediastinal and hilar lymphadenopathy of up to
20 mm and unchanged pulmonary nodules (Figure 2a,b).
Bronchoalveolar lavage was performed and PCR revealed
presence of both M. tuberculosis and CMV (191,000 CMV
copies/ml). Additionally, sputum samples were found posi-
tive for both microscopic and cultural detection of M.
tuberculosis. Tuberculostatic therapy consisting of isoniazid,
rifampicin, ethambutol and pyrazinamide was initiated.
EBV and CMV replication was also detected in the periph-
eral blood by quantitative PCR (99,300 and 53,800 copies/
ml, respectively). Intravenous ganciclovir was initiated and
rituximab was administered three times (375 mg/m2/dose)
with subsequent dropping of copy numbers of EBV and
CMV below the detection limits. Two weeks after initiation
of TB therapy the patient had completely recovered from
all infectious symptoms and sputum samples turned
negative for M. tuberculosis. The patient was subse-
quently discharged from the hospital for outpatient
continuation of tuberculostatic therapy. Unfortunately,
bone marrow examination on day +77 revealed fulmin-
ant relapse of the leukemia without signs of infection.
Palliative cytoreduction using hydroxyurea was initi-
ated and the patient was transferred to a hospice,
where he died three weeks later. The patient's next of
kin consented to the publication of this report.
Discussion
Fever in patients after allogeneic stem cell transplant-
ation can develop due to various pathogens, including
bacteria, viruses, fungi and protozoa. Tuberculosis
constitutes a rare infectious complication in patients
receiving hematopoietic stem cell transplantation in
developed countries. More frequently, active EBV repli-
cation occurs in immunocompromised hosts, potentially
leading to post-transplant lymphoproliferative disorders
(PTLDs), comprising a spectrum from polyclonal B-cell
expansion to malignant lymphoma (Swerdlow et al. 2008).
Figure 1 Histological diagnosis of synchronous nodular tuberculosis and EBV-associated lymphoproliferative disorder. Biopsy of a
cervical lymph node performed on day +36 showed effacement of the architecture due to numerous granulomas (low magnification (a), which
were composed of epithelioid cells (b). Between the granulomas a polymorphous lymphoid infiltrate was noted containing blasts as well as
plasma cells (c). The blasts were latently EBV-infected as shown in the immunohistochemical demonstration of EBNA2 (d).
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pulmonary and nodular TB as well as EBV-associated
polymorphic PTLD and CMV infection after ASCT.
This case features several remarkable issues. TB in
ASCT is usually confined to patients from endemic
areas (Garces Ambrossi et al. 2005). This case illus-
trates that TB should be included in an extended dif-
ferential diagnosis in patients with fever even if from a
non-endemic background and if other reasons explain-
ing pyrexia are present. While it is not possible to def-
initely determine the route of infection in this patient,
reactivation of latent TB seems the most likely sce-
nario, because calcified pulmonary granulomas could
be noted weeks before clinical onset of symptoms. In
addition, the patient reported exposure to TB decades
earlier, TB prevalence is low in Germany and reverse
isolation measures were observed during neutropenia,
making de novo infection less probable. This patient is
the first to be diagnosed with TB in a total of 906 pa-
tients transplanted at our institution between 2001 and
2012. This low number is likely attributable to the low
incidence of TB in Germany. However, fluoroquino-
lones have proven active in TB and have even been
used as TB-prophylaxis by other centers in certain
cases (Ip et al. 1998). Therefore, the use of ciprofloxa-
cin as anti-bacterial prophylaxis at our institution
could have contributed to the low TB incidence in
patient transplanted at our center. However, ciprofloxa-
cin should generally not be considered as first-linetuberculostatic therapy as drug-resistant strains may be
encouraged to emerge. Instead, isoniazid is generally
considered first choice for empiric prophylaxis of TB
in patients undergoing ASCT (Garces Ambrossi et al.
2005).
Several risk factors are associated with TB infection
in ASCT patients. Conditioning in our patient in-
cluded 4 Gy total body irradiation, which has been
shown to interfere with alveolar macrophage function
besides its immunosuppressive effect on the host in
general (Schluger and Rom 1998). In addition, our
patient received a graft mismatched at one human
leukocyte antigen locus, which has been shown to be
associated with higher incidence of TB (Cordonnier
et al. 2004). Another frequent risk factor predisposing
for TB is GVHD, as it is associated with a delay in T-
cell subset recovery. It is likely that therapy for GVHD
further increases TB rates, although some controversy
remains as to whether the treatment effect on GVHD
outweighs its immunosuppressive effect in this regard
(Yuen and Woo 2002). However, our patient did not
show any signs of GVHD. Increased rates of TB in
ASCT patients have also been reported in patients
receiving T-cell depleted grafts (Garces Ambrossi et al.
2005). While T-cell depletion was only performed
in vivo by administration of ATG, this patient received
a relatively low T-cell count, possibly contributing to
reactivation of several infections usually prevented by
cellular immunity.
Figure 2 Radiological diagnosis of disseminated tuberculosis. CT scan of the thorax on day +43 after allogeneic stem cell transplantation
revealed a borderline sized mediastinal lymph node with central necrosis (a) as well as multiple pulmonary nodules (b).
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+26 after transplantation after recovery of neutrophils.
This is in line with previous reports that describe the
vast majority of cases to occur after engraftment
(Russo et al. 2010), likely due to slow replication times
of M. tuberculosis with symptoms developing only
after partial immune reconstitution (Yuen and Woo
2002).
There is controversy as to whether and how pre-
transplantation screening for latent tuberculosis infec-
tion should be performed (Cordonnier et al. 2004). As
the tuberculin skin test lacks sensitivity in immunocom-
promised patients, T-cell-based interferon-gamma re-
lease assays have been proposed for ASCT patients
(Moon et al. 2012). However, more studies are war-
ranted to establish the role of such assays in the contextof ASCT. In addition, screening is only effective in
TB endemic areas. Thus, we currently propose not
to routinely perform TB screening prior to ASCT in
countries not endemic for TB while considering and
searching for mycobacterial disease in patients with
persistent fever.
In summary, we describe a case of a German male
patient developing synchronous TB, EBV-associated
lymphoproliferative disorder and CMV pneumonia
after ASCT for refractory acute myeloid leukemia. To
our knowledge, this is the first case with such a com-
bination of findings. In times of increasing population
migration and increased use of T-cell depleted strat-
egies it will be important to bear a high level of suspi-
cion of mycobacterial disease in febrile patients even in
countries with traditionally low TB prevalence.
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